Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Non-Current Deffered Revenue (2016 - 2025)

Standard Biotools (LAB) has disclosed Non-Current Deffered Revenue for 16 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 92.76% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 million, a 92.76% decrease, with the full-year FY2024 number at $32.7 million, up 828.24% from a year prior.
  • Non-Current Deffered Revenue was $2.4 million for Q3 2025 at Standard Biotools, down from $2.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $33.9 million in Q1 2024 to a low of $2.4 million in Q3 2025.
  • A 5-year average of $12.1 million and a median of $5.8 million in 2022 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 840.76% in 2024, then plummeted 92.76% in 2025.
  • Standard Biotools' Non-Current Deffered Revenue stood at $6.0 million in 2021, then tumbled by 36.04% to $3.8 million in 2022, then fell by 7.76% to $3.5 million in 2023, then surged by 828.24% to $32.7 million in 2024, then crashed by 92.76% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Non-Current Deffered Revenue are $2.4 million (Q3 2025), $2.8 million (Q2 2025), and $32.5 million (Q1 2025).